ベバシズマブ動脈内注射による慢性硬膜下血腫の治療 (CHAI)
アバスチン® (ベバシズマブ) 動脈内注射による慢性硬膜下血腫の治療: 非ランダム化非盲検第 1/2 相臨床試験
The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH).
The main questions it aims to answer are:
- Is bevacizumab infusion safe in cSDH patients?
- Is bevacizumab infusion effective in treating cSDH?
調査の概要
詳細な説明
This protocol was originally proposed as a phase I/II trial. Phase 1 was completed; planned phase 2 was discontinued prior to initiation.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- Cooper University Health Care
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Adult patients (≥18 years)
-
Radiographic evidence of chronic subdural hematoma, including
- Persistence of subdural blood more than 10 days after index traumatic injury or event
- Presence of mixed density blood
- Presence of subdural membranes
-
Can obtain informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.
Exclusion Criteria:
- Pregnant, breastfeeding, or unwilling to practice contraception during participation in the study.
- Patients with concomitant intracranial pathology other than subdural hematoma (e.g., intracranial malignancy).
- Patients with known hypersensitivity to bevacizumab.
- Patients with radiographic evidence of mass effect.
- Patients have focal neurological deficits attributed to subdural hematoma.
- Patient had craniotomy or burr hole operative procedures performed in preceding two weeks prior to onset of subdural hematoma.
- Secondary causes apart from trauma for the chronic subdural hematoma, such as underlying vascular abnormality or tumor.
- Emergent surgical evacuation is required for the patient.
- Non-convexity chronic subdural hematoma, as the middle meningeal artery will not supply this area.
- Coagulation abnormalities, including platelet count <100,000 and/or international normalized ratio of <1.5 despite attempts for correction.
- Patients with known contraindications for angiography. Patients with contrast allergy will be premedicated with diphenhydramine and steroids.
- Patient has known active systemic infection or sepsis.
- Patient has contradiction to anesthetic agents used for conscious sedation/monitored anesthesia care (MAC).
- Patient has life expectancy of less than six months due to comorbid terminal conditions.
- Patient has a premorbid modified Rankin score (mRS) of 5 or greater.
- Concurrent participation in another research protocol for investigation of an experimental therapy.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Phase 1 Unilateral cSDH/ 2mg/kg Arm
During phase 1, single 2mg/kg dose of bevacizumab to treat unilateral cSDH |
Single 2mg/kg dose of bevacizumab to treat unilateral cSDH |
|
実験的:Phase 1 Bilateral cSDH/ 4mg/kg Arm
During phase 1, two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH |
Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants with Serious Adverse Events
時間枠:Up to 3 months after study treatment
|
Reported serious adverse events classified using MedDRA and CTCAE, in addition to treatment-related events and all other adverse events |
Up to 3 months after study treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate of Hematoma Recurrence
時間枠:3 months after study treatment and 6 months after study treatment
|
Rate of hematoma recurrence or progression requiring intervention and/or readmission |
3 months after study treatment and 6 months after study treatment
|
|
Rate of Complete Hematoma Resolution
時間枠:3 months after study treatment and 6 months after study treatment
|
Rate of complete hematoma resolution compared to baseline on imaging |
3 months after study treatment and 6 months after study treatment
|
|
Rate of Partial Hematoma Resolution
時間枠:3 months after study treatment and 6 months after study treatment
|
Rate of at least 50% or greater reduction in hematoma size from baseline on imaging |
3 months after study treatment and 6 months after study treatment
|
|
Change in Hematoma Size
時間枠:3 months after study treatment and 6 months after study treatment
|
Change in hematoma size measured in millimeters on imaging |
3 months after study treatment and 6 months after study treatment
|
|
Change in Clinical Neurological Symptom Scale Scores: NIHSS
時間枠:3 months after study treatment and 6 months after study treatment
|
Change in National Institutes of Health Stroke Scale (NIHSS) scores, scores range from 0 to 42, with higher scores indicating more severe neurological deficit |
3 months after study treatment and 6 months after study treatment
|
|
Change in Clinical Neurological Symptom Scale Scores: GCS
時間枠:3 months after study treatment and 6 months after study treatment
|
Change in Glasgow Coma Scale (GCS) scores, ranging from 3 to 15 with lower score indicating more impaired consciousness |
3 months after study treatment and 6 months after study treatment
|
|
Change in Clinical Neurological Symptom Scale Scores: mRS
時間枠:3 months after study treatment and 6 months after study treatment
|
Change in modified Rankin Scale (mRS) scores, ranges from 0-6 with higher score indicating worse functional outcome |
3 months after study treatment and 6 months after study treatment
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants with Anatomical Variants
時間枠:During the treatment procedure
|
Middle meningeal arteries with dangerous anastomoses observed on imaging |
During the treatment procedure
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Manisha Koneru, MD、The Cooper Health System
- 主任研究者:Jane Khalife, MD、The Cooper Health System
- スタディチェア:Ajith J Thomas, MD、The Cooper Health System
出版物と役立つリンク
一般刊行物
- Khalife J, Koneru M, Thomas AJ. Inflammation as a Key Driver for Chronic Subdural Hematomas. Stroke. 2026 Jul;57(7):1908-1919. doi: 10.1161/STROKEAHA.126.055340. Epub 2026 May 27.
- Khalife J, Koneru M, Tonetti DA, Shaikh HA, Jovin TG, Patel PD, Thomas AJ. Intra-arterial Selective Bevacizumab Administration in the Middle Meningeal Artery for Chronic Subdural Hematoma: An Early Experience in 12 Hemispheres. Stroke Vasc Interv Neurol. 2024 Jul 22;4(5):e001409. doi: 10.1161/SVIN.124.001409. eCollection 2024 Sep.
- Khalife J, Tonetti DA, Shaikh H, Jovin T, Patel P, Thomas A. Intraarterial Bevacizumab Administration Through the Middle Meningeal Artery for Chronic Subdural Hematoma. Stroke Vasc Interv Neurol. 2023 Feb 25;3(4):e000722. doi: 10.1161/SVIN.122.000722. eCollection 2023 Jul.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 23-154
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。